Related Experiment Videos
Iproniazid-induced biochemical changes in mice
Research Communications in Chemical Pathology and Pharmacology
|July 1, 1979
Abstract:
Single doses of iproniazid to Swiss-Webster mice caused a prolonged hypoglycemic reaction and transient biphasic changes in liver triglycerides. In contrast, the same dose of iproniazid in mice on a pyridoxine deficient diet elevated plasma glucose and FFA and liver FFA and TGL. Administration of the same dose of ipioniazid for 30 days elevated liver TGL in Swiss-Webster, C57/B1, DBA, and AKR mice; this effect was reversed in all but the AKR mice when the animals were maintained on a pyrodoxine-deficient diet.
Insights
Iproniazid affects blood glucose and liver fats differently based on diet and duration. Pyridoxine deficiency alters iproniazid
Area of Science:
- Biochemistry
- Pharmacology
- Animal Models
Background:
- Iproniazid is a monoamine oxidase inhibitor.
- Dietary factors, such as pyridoxine, can influence drug metabolism and effects.
- Understanding drug-induced metabolic changes is crucial for safety and efficacy.
Purpose of the Study:
- To investigate the effects of iproniazid on glucose and lipid metabolism in mice.
- To determine the role of pyridoxine deficiency in modulating iproniazid's metabolic effects.
- To examine the impact of chronic iproniazid administration on liver triglycerides.
Main Methods:
- Administration of single and multiple doses of iproniazid to Swiss-Webster mice.
- Utilizing pyridoxine-deficient diets in conjunction with iproniazid treatment.
- Measuring plasma glucose, free fatty acids (FFA), and liver triglycerides (TGL).
- Comparing effects across different mouse strains (Swiss-Webster, C57/B1, DBA, AKR).
Main Results:
- Single iproniazid doses induced hypoglycemia and transient liver triglyceride changes in normal mice.
- In pyridoxine-deficient mice, iproniazid elevated plasma glucose, FFA, and liver FFA/TGL.
- Chronic iproniazid administration increased liver TGL in multiple strains, an effect reversed by pyridoxine deficiency, except in AKR mice.
Conclusions:
- Iproniazid's metabolic effects are significantly influenced by pyridoxine status.
- Pyridoxine deficiency exacerbates certain adverse metabolic effects of iproniazid.
- Strain-specific differences exist in the response to iproniazid, particularly concerning pyridoxine deficiency.